vaccine company in Chengdu

Clover Biopharmaceuticals is a global clinical-stage biotechnology company headquartered in Chengdu, China, dedicated to developing transformative biologics and vaccines. The company utilizes its proprietary Trimer-Tag technology platform to create novel, trimerized fusion proteins that target various diseases, including infectious diseases and cancer. Clover gained significant international prominence for its COVID-19 vaccine candidate, SCB-2019, which demonstrated high efficacy in global Phase 3 trials and received EUL from the WHO. Beyond COVID-19, the company is advancing a diverse pipeline including candidates for RSV and seasonal influenza, as well as biosimilars for inflammatory diseases. Clover maintains strategic partnerships with global health organizations like CEPI and Gavi to ensure equitable access to its products.